Prescribers’ responses rating their level of knowledge/understanding on a scale of 1–5. Prescribers’ responses rating their level of knowledge/understanding.

Slides:



Advertisements
Similar presentations
The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.
Advertisements

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart summarising the process for the identification of eligible studies.
Comparison of the LL95%CI rule to PE rules with similar behaviour, when the true HR is different from the design HR: %acceptance of maximal relative benefit,
Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall.
(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.
Progesterone receptor nuclear morphology patterns in breast cancer.
Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.
Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)
Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.
Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.
Flow chart of the used methodology adapted from Moher et al
Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.
PRISMA study flow diagram
(A) Number of KRAS mutations detected by mutation concentration by each technology with 100 copies mutant allele frequency. (A) Number of KRAS mutations.
Kaplan-Meier curves for overall survival (OS) probability.
Methods distribution among the three EQAs
Changes in haemoglobin over the course of the treatment in a patient with chronic myeloid leukaemia who developed pure red cell aplasia secondary to imatinib.
Plot with best overall response and study duration.
Patients represented by 441 physicians surveyed from 19 countries, depicted in the patient journey from diagnosis to ensuing treatment with ADT. ADT, androgen.
Comparison of the LL95%CI rule with PE rules with similar behaviour: %acceptance of maximal RB for power 80% and 90% over all trials, for LL95%CI ≤0.65 rule,
Clinical courses of patients.
Kaplan-Maier survival curves of 10-year DFS (A and B) and OS (C and D) according to PS 0 and PS≥1 in patients treated with adjuvant chemotherapy after.
(A) Survival time. (A) Survival time. All patients. (a) PFS since the start of EGFR-TKI (groups A, B and C). (b) OS since the start of EGFR-TKI (groups.
Mean change from baseline in symptom scales and single-item assessments after 6 weeks of alectinib treatment according to (A) the QLQ-C30 and (B) the QLQ-LC13.
Molecular spectra of BTC
Awareness of respondents about the availability or development of specialised services for AYA where adult and paediatric cancer specialists work together.
PFS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients (n=34). mPFS, median.
Forest plots for all drugs (OS and PFS HRs combined): excellent versus reduced PS comparison and ECOG PS levels comparison (see online supplementary 1). ECOG.
Kaplan-Meier curves of OS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients.
Tumour types of patients whose cancers harboured actionable molecular alterations in our series. ACUP, adenocarcinoma with unknown primary. Other: appendix.
Patients’ most feared AEs reported to be intolerable when lasting more than 7 days at baseline, on study and at study completion (% patients); (A) grade.
Change in individual tolerability assessment between baseline and study completion. Change in individual tolerability assessment between baseline and study.
Gender representation of board members in all international societies (reference year: 2016). Gender representation of board members in all international.
Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.
Definition of health states
Application of 5-aminolevulinic acid (5-ALA) induced fluorescence during resection of a brain metastasis. Application of 5-aminolevulinic acid (5-ALA)
(A) Progression-free survival in the hormone receptor-negative cohort patients treated with PARPi versus those treated with mono chemotherapy (controls).
Objective response rate in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).
Gender representation in all international congresses (reference year 2016). Gender representation in all international congresses (reference year 2016).
Concentration-time profiles of repeated weekly infusions of (A) 720 mg and (B) 990 mg tomuzotuximab measured in individual patients before and at the end.
Health-related quality of life (HRQOL) results.
Proportion of continuous, intermittent, and limited (
Overview of cancer genetics in the SMP1 cohort: lung cancer (A), breast cancer (B), colorectal adenocarcinoma (except mucinous subtype) (C), prostate cancer.
(A) The stratified analysis for DFS because of the uncertain status of HER2, 132 patients could be calculated the recurrence risk score. (A) The stratified.
The 22 study patients: overall survival (first patient enrolled 9 May 2014, last patient enrolled 26 August 2015, censoring date 9 May 2016); primary tumour.
Comparison of the ESMO-MCBS dual rule and the dual rule with PE thresholds exhibiting similar behaviour: %acceptance of maximal RB (solid line: RB rule)
(A) Progression-free survival in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).
Immunochemical staining for HMBG3 in normal cervix, CIN III and invasive carcinomas and could show absent staining in normal cervix (A), absent to weak.
Correlation of changes in NAFCIST and PERCIST with cumulative activity with radium RaCl2 dose was negatively correlated with changes in NAFCIST.
Kaplan-Meier plot of overall survival from the time of first dose of intrathecal interleukin-2 (IT IL-2) for all patients (A, n=43) and based on the extent.
Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (
Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.
Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;
Kaplan-Meier plots of (A) time to first improvement and (B) time to first deterioration in pain in the chest, cough and dyspnoea, according to the 13-Item Quality.
Heterogeneity in the natural history of triple negative breast cancer.
Threshold utility plot: Quality-adjusted Time WIthout Symptoms of disease or Toxicity difference (trifluridine/tipiracil vs placebo) after a median follow-up.
Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.
Clinical characteristics at diagnosis of brain metastases.
Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.
Dot plots comparing changes in renal function at pretreatment and after the first and last cycles in both hydration groups. Dot plots comparing changes.
(A) Survival curves according to clinical response.
Total number of KRAS variants identified and discussed by the Genomics Review Board from all Sarah Cannon Molecular Diagnostics reports. Total number of.
Time to progression and overall survival for patients according to four factors (in order, top to bottom): debulking surgery or not, residual disease after.
Kaplan-Meier estimates for survival in metastatic disease for the whole patient cohort (A) and in patients with or without history of adjuvant trastuzumab.
Time to progression and overall survival for patients who had dose-dense chemotherapy, according to two factors (in order, top to bottom): type of dose-dense.
Prescribers’ responses rating their level of comfort on a scale of 1–5
Meta-analysis of the effect of gender in the overall survival, comparing HRs and 95% CI obtained from multivariate analysis in hospital databases. Meta-analysis.
Presentation transcript:

Prescribers’ responses rating their level of knowledge/understanding on a scale of 1–5. Prescribers’ responses rating their level of knowledge/understanding on a scale of 1–5. Prescribers’ responses, by region, when asked to rate their knowledge/understanding of (A) biosimilars overall; (B) the biosimilar development process and threshold of clinical evidence required for approval; (C) clinical trial design and endpoint selection for biosimilar studies; (D) requirements needed to be met for extrapolation of indications to be granted for a biosimilar. Rosa Giuliani et al. ESMO Open 2019;4:e000460 Copyright © European Society for Medical Oncology. All rights reserved.